Related Experiment Videos
Lymphoblastic lymphoma following prenatal exposure to phenytoin
J C Murray1, R M Hill, S Hegemier
1Texas Children's Cancer Center, Baylor College of Medicine, Houston, USA.
Insights
Prenatal phenytoin exposure may increase cancer risk in children, including rare T-lymphocyte lymphoblastic lymphoma. Further research is needed to understand this association and its mechanisms.
Area of Science:
- Pharmacology
- Oncology
- Developmental Biology
Background:
- Prenatal exposure to phenytoin is linked to oncogenesis, often presenting as embryonal tumors of neural crest origin within the first three years of life.
- The exact oncogenic potential and epidemiological data regarding phenytoin's transplacental effects remain largely unelucidated.
Observation:
- A case report details a male infant exposed to phenytoin throughout gestation who subsequently developed T-lymphocyte lymphoblastic lymphoma.
- This represents a previously undocumented malignancy associated with in utero phenytoin exposure.
Findings:
- The study tabulates previously reported neoplasia cases linked to prenatal phenytoin exposure.
- Phenytoin may exert its oncogenic effects through alterations in lymphocyte-mediated immunosurveillance or oxidative metabolic clearance.
Implications:
- Clinicians should investigate prenatal phenytoin exposure in children diagnosed with cancer, particularly rare tumors or common tumors presenting at an unusually young age.
- Continued case documentation is crucial for advancing the understanding of phenytoin-associated transplacental oncogenesis.
Purpose:
Oncogenesis has been associated with prenatal exposure to phenytoin, concomitant with or independent of the fetal hydantoin syndrome. The majority of reported cases have been embryonal tumors of neural crest origin and have occurred in the first 3 years of life.
Patients And Methods:
We report a boy who was exposed to phenytoin throughout gestation and later developed T-lymphocyte lymphoblastic lymphoma, a previously unreported malignancy associated with in utero phenytoin exposure. Previously reported cases of neoplasia occurring after such exposure are tabulated.
Conclusion:
The actual transplacental oncogenic potential of phenytoin and the epidemiology of this association are poorly understood. Phenytoin-induced alterations in lymphocyte-mediated immunosurveillance or oxidative metabolic clearance may be etiologic. Inquiry into prenatal phenytoin exposure should be done in any child who develops cancer, especially those who develop a rare tumor or present with a more common tumor at an unusually young age. Continued documentation of such cases will advance the understanding of phenytoin-associated transplacental oncogenesis.